Blog Post by Admin
Presentation
Apr 27, 2022
Utility Assessments in Synthetic Data
Start Reading
Blog
Apr 19, 2022
RWE Guidance: NICE’s RWE Framework
This month, the UK’s National Institute for Health and Care Excellence (NICE) released ...
Start Reading
Publication
Apr 15, 2022
Utility Metrics for Evaluating Synthetic Health Data Generation Methods: Validation Study
Start Reading
Presentation
Mar 30, 2022
Managing and Regulating Privacy Risks in Synthetic Data
Start Reading
Presentation
Feb 9, 2022
Synthetic Data Generation 101
Start Reading
Blog
Feb 9, 2022
Aetion’s comments to FDA on data standards for RWD in drug and biological product submissions
Last week, Aetion submitted a letter to FDA commenting on the Agency’s recent draft ...
Start Reading
Blog
Feb 3, 2022
Aetion’s comments to FDA on electronic health records and claims to support regulatory decisions
Last week, Aetion submitted a letter to FDA commenting on the Agency’s recent draft ...
Start Reading
Blog
Jan 28, 2022
Understanding propensity score weighting methods
Oftentimes researchers want to compare two medications—an existing medication to a newly ...
Start Reading
Blog
Jan 4, 2022
Why we acquired synthetic data pioneer Replica Analytics
The potential for real-world evidence (RWE) to improve patient lives and better protect ...
Start Reading
Blog
Dec 22, 2021
What I learned from former FDA leaders during Aetion’s RWE Summit
Aetion hosted our annual RWE Summit in New York last month, and I am still inspired by ...
Start Reading
Blog
Dec 21, 2021
Research spotlight: Using RWE to characterize prescription opioid dispensing patterns after surgical abortion
Over 800,000 abortions occur annually in the United States, the majority of which are ...
Start Reading
Presentation
Dec 1, 2021
Generating Synthetic Longitudinal Data
Start Reading
Blog
Nov 18, 2021
What industry can learn from RWE demonstration projects
As global regulatory and health technology assessment (HTA) bodies continue to iterate on ...
Start Reading
Blog
Nov 12, 2021
RWE guidance watch: EMA real world evidence guidance on registry-based studies
UPDATE: As of November 2021, EMA has now issued its final guideline on registry-based ...
Start Reading
Blog
Oct 29, 2021
COVID-19 vaccine rollout shows real-world evidence was ready for the spotlight
Just 10 months since administration of the first COVID-19 vaccine dose, hundreds of ...
Start Reading
Presentation
Oct 27, 2021
Synthetic Data Generation for Rare Disease Research
Start Reading
Blog
Sep 30, 2021
Join primary and real-world data to generate patient-relevant RWE across the product lifecycle: Q&A with Dr. Javier Jimenez of Syneos Health
Understanding how medical interventions impact patients has always been a top priority ...
Start Reading
Presentation
Sep 22, 2021
Measuring Re-identification Risk for Synthetic and Anonymized Data
Start Reading
Presentation
Sep 13, 2021
Synthetic Data
Start Reading
Blog
Sep 9, 2021
ICPE Research Spotlight 2021: Part II: Forging methods to advance principled database epidemiology
This year at ICPE All Access, Aetion’s scientific research was represented across ...
Start Reading
Presentation
Sep 2, 2021
Practical Mechanisms for Generating Anonymous Data
Start Reading
Presentation
Sep 1, 2021
Ten Recommendations For Regulating De-identification
Start Reading
Blog
Aug 26, 2021
ICPE Research Spotlight 2021: Part I: Findings from Aetion-FDA research collaboration to advance understanding of COVID-19 with RWE
This year at ICPE All Access, Aetion’s scientific research is represented across ...
Start Reading
Blog
Aug 26, 2021
RWE to inform value decision-making: Learnings from ICER’s 24-month reassessment pilot
In its 2020 Value Assessment Framework, the Institute of Clinical and Economic Review ...
Start Reading